Business
Transgene’s Individualized Neoantigen Therapeutic Cancer Vaccine TG4050 Delivers Positive Randomized Phase I Data Randomization to be Completed in Phase II Part in Q4 2025
2025 Half-Year Results and Business Update Positive Phase I data with TG4050 in operable Head and Neck Squamous Cell Carcinoma (HNSCC) 100% disease-free survival after 2 years of follow-up — data presented in a rapid oral presentation at ASCO (June 2025) Transgene to report additional immunological data at a scientific conference in Q4 2025 Ongoing Phase II part with TG4050 in operable HNSCC Patient screening completed, completion of randomization expected in Q4 2025First immunogenicity data exp
About this update from Transgene Sa
[{"type":"image","alt":"Transgene S.A.","displaySize":"","headline":null,"caption":"Transgene S.A.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":87,"url":"https://media.zenfs.com/en/globenewswire.com/5d1fdb58becb1cac5f93d4611349f00f"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/oNK.3ZmCdoUtYmU0w8KFwQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEyMjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/5d1fdb58becb1cac5f93d4611349f00f","width":300,"height":87}},"lazy":false},{"type":"text","content":"2025 Half-Year Results and Business Update","length":42,"tagName":"p"},{"type":"text","content":"Positive Phase I data with TG4050 in operable Head and Neck Squamous Cell Carcinoma (HNSCC) ","length":91,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"100% disease-free survival after 2 years of follow-up — data presented in a rapid oral presentation at ASCO (June 2025)","length":119,"tagName":"p"}]},{"val":[{"type":"text","content":"Transgene to report additional immunological data at a scientific conference in Q4 2025","length":92,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":211,"olType":false},{"type":"text","content":"Ongoing Phase II part with TG4050 in operable HNSCC","length":56,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Patient screening completed, completion of randomization expected in Q4 2025","length":81,"tagName":"p"}]},{"val":[{"type":"text","content":"First immunogenicity data expected in H2 2026, and efficacy data expected in Q4 2027","length":94,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":175,"olType":false},{"type":"text","content":"Preparing new Phase I trial in an additional indication","length":55,"tagName":"p"},{"type":"text","content":"Business funded until the end of December 2026 ","length":46,"tagName":"p"},{"type":"text","content":"Conference call scheduled today at 6 p.m. CET (in English). See details below.","length":83,"tagName":"p"},{"type":"text","content":"Strasbourg, France, September 16, 2025, 5:45 pm CET — Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today announces its financial results for the six-month period ended June 30, 2025, and provides an update on the myvac® pla...